Promising novel cytotoxic agents and combinations in metastatic prostate cancer

Cancer Journal

Volumn 14, Issue 1, 2008, Pages 15-19

  Bradley, Deborah A ^a   Hussain, Maha ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Chemotherapy; Cytotoxic therapy; Hormone refractory prostate cancer; Metastatic; Targeted therapy

Indexed keywords

1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; AFLIBERCEPT; ATRASENTAN; BEVACIZUMAB; CALCITRIOL; CETUXIMAB; CP 751871; CYTOTOXIC AGENT; DASATINIB; DOCETAXEL; ENZASTAURIN; ERIBULIN; ESTRAMUSTINE; EVEROLIMUS; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; ISOSORBIDE; ISPINESIB; IXABEPILONE; MITOXANTRONE; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; OGX 011; PACLITAXEL; PANOBINOSTAT; PREDNISONE; SATRAPLATIN; SORAFENIB; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; 2 (3 AMINO 2 HYDROXYPROPYL)HEXACOSAHYDRO 3 METHOXY 26 METHYL 20,27 BIS(METHYLENE)11,15 18,21 24,28 TRIEPOXY 7,9 ETHANO 12,15 METHANO 9H,15H FURO(3,2 I)FURO(2',3' 5,6)PYRANO(4,3 B)(1,4)DIOXACYCLOPENTACOSIN 5 (4H) ONE; 2-(3-AMINO-2-HYDROXYPROPYL)HEXACOSAHYDRO-3-METHOXY-26-METHYL-20,27-BIS(METHYLENE)11,15-18,21-24,28-TRIEPOXY-7,9-ETHANO-12,15-METHANO-9H,15H-FURO(3,2-I)FURO(2',3'-5,6)PYRANO(4,3-B)(1,4)DIOXACYCLOPENTACOSIN-5-(4H)-ONE; ALBUMIN BOUND PACLITAXEL; ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; CANCER VACCINE; CYTOTOXIN; EPOTHILONE DERIVATIVE; FURAN DERIVATIVE; KETONE; PLATINUM COMPLEX; QUINAZOLINE DERIVATIVE; TAXOID;

ANGIOGENESIS; BLOOD TOXICITY; BONE METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL TRIAL; COLON CANCER; DRUG FATALITY; DRUG POTENTIATION; DRUG PROTEIN BINDING; HUMAN; METASTASIS; MICROTUBULE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; UNSPECIFIED SIDE EFFECT; VACCINIA VIRUS; MALE; PATHOLOGY; PATHOPHYSIOLOGY; PROSTATE TUMOR;

ALBUMINS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; CALCITRIOL; CANCER VACCINES; CYTOTOXINS; EPOTHILONES; FURANS; HUMANS; KETONES; MALE; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; PROSTATIC NEOPLASMS; QUINAZOLINES; TAXOIDS;

EID: 43049154852     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31816220b7     Document Type: Review

References (59)

1. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormoneresistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756-1764.
2. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17:2506-2513.
3. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
4. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
5. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 2004;64:9209-9216.
6. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401-410.
7. Jimenez JA, Kao C, Raikwar S, et al. Current status of anti-angiogenesis therapy for prostate cancer. Urol Oncol. 2006;24:260-268.
8. Bok RA, Halabi S, Fei DT, et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a Cancer and Leukemia Group B Study. Cancer Res. 2001;61:2533-2536.
9. Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143:401-409.
10. Shariat SF, Anwuri VA, Lamb DJ, et al. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol. 2004;22:1655-1663.
11. Borre M, Nerstrom B, Overgaard J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res. 2000;6:1882-1890.
12. Kohli M, Kaushal V, Spencer HJ, et al. Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer. Urology. 2003; 61:765-769.
13. Reese D, Harris K, Corry M, et al. A phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. Prostate J. 2001;3:65-70.
14. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
15. Picus J, Halabi S, Rini B, et al. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): initial results of CALGB 90006. Proc Am Soc Clin Oncol. 2003;22:1578.
16. Ryan CJ, Lin AM, Small EJ. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale. Urol Oncol. 2006;24:250-253.
17. Verheul HM, Hammers H, van Erp K, et al. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res. 2007;13:4201-4208.
18. Bradley DA, Hussain M, Dipaola RS, et al. Bone directed therapies for prostate cancer J Urol. 2007;178:S42-S48.
19. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995;1:944-949.
20. Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A. 2003;100:10954-10959.
21. Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate. 2000;44:77-87.
22. Thakkar SG, Choueiri TK, Garcia JA. Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics. Curr Oncol Rep. 2006;8:108-113.
23. Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res. 2006;12:6296s-6300s.
24. Vogelzang N, Nelson J, Schulman C, et al. Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2005;23:4563.
25. Banerjee S, Hussain M, Wang Z, et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res. 2007;67:3818-3826.
26. D'Amico AV, Moul JW, Carroll PR, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95:1376-1383.
27. Morris CD, Rose A, Curwen J, et al. Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br J Cancer. 2005;92:2148-2152.
28. James ND, Borre M, Zonnenberg B, et al. ZD4054, a potent, specific endothelin A receptor antagonist, improves overall survival in pain-free or mildly symptomatic patients with hormone-resistant prostate cancer (HRPC) and bone metastases. Eur J Cancer. 2007;5(suppl). Abstract 3LB.
29. Beer TM. ASCENT: the Androgen-Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere. BJU Int. 2005;96:508-13.
30. Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol. 2007;25:669-674.
31. Basler M, Groettrup M. Advances in prostate cancer immunotherapies. Drugs Aging. 2007;24:197-221.
32. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24:3089-3094.
33. McNeel DG. Prostate cancer immunotherapy. Curr Opin Urol. 2007;17: 175-181.
34. Arlen PM, Gulley JL, Parker C, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res. 2006;12: 1260-1269.
35. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol. 1999;17:1061-1070.
36. Attard G, Greystoke A, Kaye S, et al. Update on tubulin-binding agents. Pathol Biol (Paris). 2006;54:72-84.
37. Hudes G, Einhorn L, Ross E, et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol. 1999;17:3160-3166.
38. Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubulestabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol®). J Biol Chem. 1997;272:2534-2541.
39. Nettles JH, Li H, Cornett B, et al. The binding mode of epothilone A on α,β-tubulin by electron crystallography. Science. 2004;305:866-869.
40. Hussain M, Tangen CM, Lara PN Jr, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol. 2005;23:8724-8729.
41. Galsky MD, Small EJ, Oh WK, et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol. 2005;23:1439-1446.
42. Rosenberg JE, Weinberg VK, Kelly WK, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer. 2007;110:556-563.
43. Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005;4:1086-1095.
44. Towle MJ, Salvato KA, Budrow J, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001;61:1013-1021.
45. Davis DA, Sarkar SH, Hussain M, et al. Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line. BMC Cancer. 2006;6:22.
46. John TA, Vogel SM, Tiruppathi C, et al. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol. 2003;284:L187-L196.
47. Ho CC, Huang PH, Huang HY, et al. Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol. 2002;161:1647-1656.
48. Kato K, Hida Y, Miyamoto M, et al. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer. 2002;94:929-933.
49. Tahir SA, Yang G, Ebara S, et al. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res. 2001;61:3882-3885.
50. Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophorfree, albumin-bound paclitaxel, ABI-007, compared with Cremophorbased paclitaxel. Clin Cancer Res. 2006;12:1317-1324.
51. Thomas R, True LD, Bassuk JA, et al. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res. 2000;6:1140-1149.
52. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794-7803.
53. Gradishar W, Krasnojon D, Cheporov S, et al. A randomized phase 2 trial of qw or q3w ABI-007 (ABX) vs. q3W solvent-based docetaxel (TXT) as first-line therapy in metastatic breast cancer (MBC). Paper presented at: San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, TX. Abstract 46.
54. Jacob K, Webber M, Benayahu D, Kleinman HK. Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res. 1999;59:4453-4457.
55. De S, Chen J, Narizhneva NV, et al. Molecular pathway for cancer metastasis to bone. J Biol Chem. 2003;278:39044-39050.
56. Li L, Yang G, Ebara S, et al. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res. 2001;61:4386-4392.
57. Yang G, Truong LD, Timme TL, et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res. 1998;4: 1873-1880.
58. Sternberg CN, Whelan P, Hetherington J, et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology. 2005;68:2-9.
59. Sternberg CN, Petrylak D, Witjes F, et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: results of a randomized phase III trial. J Clin Oncol. 2007;25:5019.